Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

Conditions:   Acute Ischemic Stroke;   Acute Renal Injury Interventions:   Drug: Conestat alfa (Ruconest®);   Drug: NaCl 0.9%) Sponsors:   University Hospital, Basel, Switzerland;   Swiss National Science Foundation;   Pharming Technologies B.V. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials